Eidos Therapeutics, Inc. (EIDX) financial statements (2020 and earlier)

Company profile

Business Address 101 MONTGOMERY STREET, SUITE 2550
SAN FRANCISCO, CA 94104
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

9/30/2019
TTM
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments166157
Cash and cash equivalents166157
Receivables00
Other undisclosed current assets52
Total current assets:171159
Noncurrent Assets
Operating lease, right-of-use asset4
Property, plant and equipment10
Other noncurrent assets21
Total noncurrent assets:81
TOTAL ASSETS:179160
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities62
Accounts payable42
Accrued liabilities10
Employee-related liabilities10
Debt0 
Deferred compensation liability00
Due to related parties00
Other undisclosed current liabilities32
Total current liabilities:105
Noncurrent Liabilities
Long-term debt and lease obligation5 
Operating lease, liability5
Liabilities, other than long-term debt00
Other liabilities00
Total noncurrent liabilities:50
Total liabilities:155
Stockholders' equity
Stockholders' equity attributable to parent164155
Common stock00
Additional paid in capital248220
Accumulated deficit(84)(65)
Total stockholders' equity:164155
TOTAL LIABILITIES AND EQUITY:179160

Income statement (P&L) ($ in millions)

9/30/2019
TTM
12/31/2018
Revenues
(Other undisclosed Revenues)
27 
Cost of revenue
(Cost of Goods and Services Sold)
(3) 
Gross profit:24 
Operating expenses(55)(38)
Operating loss:(31)(38)
Nonoperating income (expense)
(Other Nonoperating Income (Expense))
1(3)
Other undisclosed income from continuing operations before equity method investments, income taxes7 
Net loss attributable to parent:(23)(41)
Other undisclosed net income available to common stockholders, basic11
Net loss available to common stockholders, diluted:(22)(40)

Comprehensive Income ($ in millions)

9/30/2019
TTM
12/31/2018
Net loss:(23)(41)
Comprehensive loss, net of tax, attributable to parent:(23)(41)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: